Design
Review
Authors
Loading...
Metabolic changes in HF should not prompt targeted therapies; leaves open whether primary defects exist in specific subtypes.
Key points are not available for this paper at this time.
P POOLEWILSON (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: